Edition:
United Kingdom

Galmed Pharmaceuticals Ltd (GLMD.OQ)

GLMD.OQ on NASDAQ Stock Exchange Capital Market

6.09USD
20 Apr 2018
Change (% chg)

$-0.18 (-2.87%)
Prev Close
$6.27
Open
$6.25
Day's High
$6.25
Day's Low
$6.07
Volume
2,253
Avg. Vol
18,319
52-wk High
$12.00
52-wk Low
$3.61

Latest Key Developments (Source: Significant Developments)

Galmed Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln
Monday, 26 Mar 2018 

March 26 (Reuters) - Galmed Pharmaceuticals Ltd ::GALMED PHARMACEUTICALS LTD FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Galmed Pharmaceuticals Q4 Loss Per Share $0.27
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Galmed Pharmaceuticals Ltd ::GALMED PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 REVENUE $300,000 VERSUS I/B/E/S VIEW $289,000.Q4 LOSS PER SHARE $0.27.  Full Article

683 Capital Management Llc Reports 5.1 Pct Passive Stake In Galmed Pharmaceuticals Ltd As Of Dec 6
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Galmed Pharmaceuticals Ltd ::683 CAPITAL MANAGEMENT LLC REPORTS 5.1 PERCENT PASSIVE STAKE IN GALMED PHARMACEUTICALS LTD AS OF DEC 6 - SEC FILING.  Full Article

Galmed Pharmaceuticals Q3 loss per share $0.23
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Galmed Pharmaceuticals Ltd :Galmed Pharmaceuticals reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.23.Q3 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.Q3 revenue $300,000 versus I/B/E/S view $319,000.Galmed Pharmaceuticals - ‍cash, cash equivalents,marketable securities totaled $9.0 million as of Sept 30, compared to $15.5 million at December 31, 2016​.Galmed Pharmaceuticals Ltd - ‍Galmed believes that its cash balance will be sufficient to maintain its current operations through 2018​.  Full Article

Galmed Pharmaceuticals signed agreement with University of California
Thursday, 22 Sep 2016 

Galmed Pharmaceuticals Ltd : Signed an investigator-initiated clinical trial agreement with University of California, San Diego, school of medicine .Artisan study is currently expected to be initiated in first half of 2017.  Full Article

Galmed Pharmaceuticals Q2 loss per share $0.39
Wednesday, 3 Aug 2016 

Galmed Pharmaceuticals Ltd : Q2 loss per share $0.39 .Expect that its cash balance will be sufficient to maintain its current operations through second half of 2017..  Full Article

Galmed and Samil Pharm sign deal for Aramchol(Tm) in Korea
Thursday, 28 Jul 2016 

Galmed Pharmaceuticals Ltd : Galmed Pharmaceuticals And Samil Pharm sign a license agreement for the commercialization of aramchol(tm) in Korea . Upon signing of agreement, samil will pay galmed an up-front fee of approximately $2.0 million .Samil has also agreed to pay additional clinical- and regulatory-based milestone payments, which may aggregate to $6.0 million.  Full Article

Galmed Pharmaceuticals says enters research collaboration agreement
Thursday, 30 Jun 2016 

Galmed Pharmaceuticals Ltd : Has right to enter into exclusive negotiations with Yeda to complete license agreement to commercialize diagnostic, prognostic tool for Aramchol .Galmed Pharmaceuticals and Weizmann Institute of Science to enter a research collaboration agreement to assess Aramchol(tm) effects on microbiome.  Full Article

Galmed Pharmaceuticals posts Q1 loss of $0.36 per share
Monday, 16 May 2016 

Galmed Pharmaceuticals Ltd : Galmed Pharmaceuticals reports first quarter 2016 financial results and provides business update . Q1 loss per share $0.36 .Q1 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.  Full Article

  • Previous
  • Next

Galmed Pharmaceuticals Ltd News

BRIEF-Galmed Pharmaceuticals Announces Pricing Of $6 Mln Registered Direct Offering

* ANNOUNCES PRICING OF $6.0 MILLION REGISTERED DIRECT OFFERING

» More GLMD.OQ News

Earnings vs. Estimates

» More Financials